ORBIMED CAPITAL LLC
CIK 1157524 · last filed 2026-04-23
ORBIMED CAPITAL LLC is a corporate insider who has filed 33 SEC Form 4 insider transactions across 7 companies since 2019. The most recent filing, for ELVN, was dated Jun 22, 2026. Across all open-market trades the lifetime net is +$39.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $96.7M across reported positions. The firm reports its address in New York, NY. 63 SEC filings were submitted jointly with ORBIMED ADVISORS LLC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$96.70M
7
33
$39.06M
Filer Profile
54TH FLOOR
NEW YORK, NY 10022
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRLD | Director | 1,126,126 | $4.59 | $5.17M | $65.00M | 3 | 2026-04-23 |
| SPRY | Director | 269,323 | $4.76 | $1.28M | -$3.26M | 1 | 2024-08-28 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 1,368,339 | $2.65 | $3.63M | $36.56M | 3 | 2023-05-08 |
| ARQT | Director | 3,534,537 | $23.89 | $84.42M | $43.84M | 3 | 2022-06-28 |
| PMVP | 10%+ Owner | 109,500 | $1.40 | $153.3K | -$41.06M | 1 | 2022-03-31 |
| Repare Therapeutics Inc. (RPTX) Delisted | Director | 3,221,637 | $2.65 | $8.54M | -$1.85M | 1 | 2021-08-30 |
| ALEC | Director | 2,650,781 | $2.14 | $5.67M | -$60.17M | 3 | 2019-12-26 |
Recent Filings
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-22 | ELVN | Notice (144) | −29,385 | -$1.35M | EDGAR |
| 2026-06-15 | ELVN | Notice (144) | −10,243 | -$433.9K | EDGAR |
| 2026-04-23 | PRLD | Buy (P) | +11,261,260 | $50.00M | EDGAR |
| 2025-04-09 | CMPX | Notice (144) | −3,571,428 | -$5.68M | EDGAR |
| 2024-12-04 | PASG | Notice (144) | −2,028,307 | -$1.81M | EDGAR |
| 2024-09-16 | PASG | Notice (144) | −241,328 | -$194.8K | EDGAR |
| 2024-08-28 | SPRY | Sell (S) | −251,085 | -$3.26M | EDGAR |
| 2024-08-21 | SPRY | Notice (144) | −952,377 | -$14.18M | EDGAR |
| 2024-05-17 | ELVN | Notice (144) | −5,500 | -$121.8K | EDGAR |
| 2023-12-11 | KROS | Notice (144) | −246,000 | -$8.77M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.